Annual Accounts Receivable
$16.12 M
+$8.93 M+124.34%
31 December 2023
Summary:
Zevra Therapeutics annual accounts receivable is currently $16.12 million, with the most recent change of +$8.93 million (+124.34%) on 31 December 2023. During the last 3 years, it has risen by +$13.68 million (+560.07%). ZVRA annual accounts receivable is now at all-time high.ZVRA Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Accounts Receivable
$7.79 M
-$1.16 M-12.93%
30 September 2024
Summary:
Zevra Therapeutics quarterly accounts receivable is currently $7.79 million, with the most recent change of -$1.16 million (-12.93%) on 30 September 2024. Over the past year, it has dropped by -$2.14 million (-21.53%). ZVRA quarterly accounts receivable is now -51.67% below its all-time high of $16.12 million, reached on 31 December 2023.ZVRA Quarterly Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ZVRA Accounts Receivable Performance
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
---|---|---|
1 y1 year | +124.3% | -21.5% |
3 y3 years | +560.1% | +381.2% |
5 y5 years | +100.0% | +375.6% |
ZVRA Accounts Receivable High & Low
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
---|---|---|---|---|---|
3 y | 3 years | at high | +1034.3% | -51.7% | +448.2% |
5 y | 5 years | at high | -51.7% | +448.2% | |
alltime | all time | at high | -51.7% |
Zevra Therapeutics Accounts Receivable History
Date | Annual | Quarterly |
---|---|---|
Sept 2024 | - | $7.79 M(-12.9%) |
June 2024 | - | $8.95 M(+7.7%) |
Mar 2024 | - | $8.30 M(-48.5%) |
Dec 2023 | $16.12 M(+124.3%) | $16.12 M(+62.4%) |
Sept 2023 | - | $9.93 M(-14.4%) |
June 2023 | - | $11.60 M(+48.3%) |
Mar 2023 | - | $7.82 M(+8.9%) |
Dec 2022 | $7.18 M(+405.6%) | $7.18 M(+9.1%) |
Sept 2022 | - | $6.58 M(+133.4%) |
June 2022 | - | $2.82 M(-15.1%) |
Mar 2022 | - | $3.32 M(+133.6%) |
Dec 2021 | $1.42 M | - |
Dec 2021 | - | $1.42 M(-12.2%) |
Sept 2021 | - | $1.62 M(-14.2%) |
June 2021 | - | $1.89 M(-83.3%) |
Date | Annual | Quarterly |
---|---|---|
Mar 2021 | - | $11.31 M(+363.1%) |
Dec 2020 | $2.44 M(+45.3%) | $2.44 M(+10.9%) |
Sept 2020 | - | $2.20 M(+5.2%) |
June 2020 | - | $2.09 M(-7.6%) |
Mar 2020 | - | $2.27 M(+34.7%) |
Dec 2019 | $1.68 M(>+9900.0%) | $1.68 M(+2.6%) |
Sept 2019 | - | $1.64 M(>+9900.0%) |
Dec 2018 | $0.00(-100.0%) | $0.00(0.0%) |
Sept 2018 | - | $0.00(-100.0%) |
Mar 2018 | - | $1.51 M(-24.6%) |
Dec 2017 | $2.00 M(-59.9%) | $2.00 M(-19.9%) |
Sept 2017 | - | $2.50 M(>+9900.0%) |
June 2017 | - | $0.00(0.0%) |
Mar 2017 | - | $0.00(-100.0%) |
Dec 2016 | $5.00 M(>+9900.0%) | $5.00 M(>+9900.0%) |
Dec 2015 | $0.00 | $0.00 |
FAQ
- What is Zevra Therapeutics annual accounts receivable?
- What is the all time high annual accounts receivable for Zevra Therapeutics?
- What is Zevra Therapeutics annual accounts receivable year-on-year change?
- What is Zevra Therapeutics quarterly accounts receivable?
- What is the all time high quarterly accounts receivable for Zevra Therapeutics?
- What is Zevra Therapeutics quarterly accounts receivable year-on-year change?
What is Zevra Therapeutics annual accounts receivable?
The current annual accounts receivable of ZVRA is $16.12 M
What is the all time high annual accounts receivable for Zevra Therapeutics?
Zevra Therapeutics all-time high annual accounts receivable is $16.12 M
What is Zevra Therapeutics annual accounts receivable year-on-year change?
Over the past year, ZVRA annual accounts receivable has changed by +$8.93 M (+124.34%)
What is Zevra Therapeutics quarterly accounts receivable?
The current quarterly accounts receivable of ZVRA is $7.79 M
What is the all time high quarterly accounts receivable for Zevra Therapeutics?
Zevra Therapeutics all-time high quarterly accounts receivable is $16.12 M
What is Zevra Therapeutics quarterly accounts receivable year-on-year change?
Over the past year, ZVRA quarterly accounts receivable has changed by -$2.14 M (-21.53%)